HSPA5 and neoplasm: In the field of immunotherapy, chimeric antigen receptor (CAR) T cells targeting cell surface GRP78 (GRP78.1x, GRP78.2x, and GRP78.3 × CAR T cells) demonstrated potent anti-tumor activity against acute myeloid leukemia (AML) cells.